313 related articles for article (PubMed ID: 27294782)
1. Functional interdependence of BRD4 and DOT1L in MLL leukemia.
Gilan O; Lam EY; Becher I; Lugo D; Cannizzaro E; Joberty G; Ward A; Wiese M; Fong CY; Ftouni S; Tyler D; Stanley K; MacPherson L; Weng CF; Chan YC; Ghisi M; Smil D; Carpenter C; Brown P; Garton N; Blewitt ME; Bannister AJ; Kouzarides T; Huntly BJ; Johnstone RW; Drewes G; Dawson SJ; Arrowsmith CH; Grandi P; Prinjha RK; Dawson MA
Nat Struct Mol Biol; 2016 Jul; 23(7):673-81. PubMed ID: 27294782
[TBL] [Abstract][Full Text] [Related]
2. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
3. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
4. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
5. Menin as a hub controlling mixed lineage leukemia.
Thiel AT; Huang J; Lei M; Hua X
Bioessays; 2012 Sep; 34(9):771-80. PubMed ID: 22829075
[TBL] [Abstract][Full Text] [Related]
6. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Waters NJ; Daigle SR; Rehlaender BN; Basavapathruni A; Campbell CT; Jensen TB; Truitt BF; Olhava EJ; Pollock RM; Stickland KA; Dovletoglou A
J Control Release; 2015 Dec; 220(Pt B):758-65. PubMed ID: 26385168
[TBL] [Abstract][Full Text] [Related]
7. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
8. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
9. Histone cross-talk connects protein phosphatase 1α (PP1α) and histone deacetylase (HDAC) pathways to regulate the functional transition of bromodomain-containing 4 (BRD4) for inducible gene expression.
Hu X; Lu X; Liu R; Ai N; Cao Z; Li Y; Liu J; Yu B; Liu K; Wang H; Zhou C; Wang Y; Han A; Ding F; Chen R
J Biol Chem; 2014 Aug; 289(33):23154-23167. PubMed ID: 24939842
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain-containing protein 4 regulates a cascade of lipid-accumulation-related genes at the transcriptional level in the 3T3-L1 white adipocyte-like cell line.
Mochizuki K; Yamada M; Inoue T; Hariya N; Kubota T; Goda T
Eur J Pharmacol; 2020 Sep; 883():173351. PubMed ID: 32650006
[TBL] [Abstract][Full Text] [Related]
11. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
Chen S; Yang Z; Wilkinson AW; Deshpande AJ; Sidoli S; Krajewski K; Strahl BD; Garcia BA; Armstrong SA; Patel DJ; Gozani O
Mol Cell; 2015 Oct; 60(2):319-27. PubMed ID: 26439302
[TBL] [Abstract][Full Text] [Related]
12. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
[TBL] [Abstract][Full Text] [Related]
13. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
14. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
15. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
16. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
17. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
18. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
19. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the DOT1L network: implications of diverse roles for DOT1L.
Park G; Gong Z; Chen J; Kim JE
Protein J; 2010 Apr; 29(3):213-23. PubMed ID: 20431927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
